ZJU-6, a novel derivative of Erianin, shows potent anti-tubulin polymerisation and anti-angiogenic activities

Investigational New Drugs

Volumn 30, Issue 5, 2012, Pages 1899-1907

  Lam, Frankie ^a   Bradshaw, Tracey D ^a   Mao, Hui ^b   Roberts, Scott ^a   Pan, Yuanjiang ^b   Wang, Shudong ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b ZHEJIANG UNIVERSITY   (China)

Author keywords

Angiogenesis; Anti oxidant; Anti tubulin polymerisation; Apoptosis; Caspase activation; Chemotherapy

Indexed keywords

AGENTS AFFECTING CELL DIVISION; ANGIOGENESIS INHIBITOR; CASPASE 3; ERIANIN; LIPOCORTIN 5; NATURAL PRODUCT; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROPIDIUM IODIDE; TUBULIN; UNCLASSIFIED DRUG; ZJU 6;

ANIMAL TISSUE; ANTI TUBULIN POLYMERIZATION ACTIVITY; ANTIANGIOGENIC ACTIVITY; ANTIOXIDANT ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BREAST CARCINOMA; CANCER CELL CULTURE; CELL FATE; CELL STRAIN MCF 7; CELL VIABILITY; COLON CARCINOMA; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG CYTOTOXICITY; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVITY; ENZYME DEGRADATION; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; INCUBATION TIME; LUNG CARCINOMA; MICROTUBULE ASSEMBLY; MITOSIS INHIBITION; NONHUMAN; PANCREAS CARCINOMA; PRIORITY JOURNAL;

ANGIOGENESIS INHIBITORS; ANNEXIN A5; ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; APOPTOSIS; BIBENZYLS; CASPASE 3; CELL CYCLE CHECKPOINTS; CELL DIVISION; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; FREE RADICAL SCAVENGERS; G2 PHASE; HUMANS; MCF-7 CELLS; MICROTUBULES; POLY(ADP-RIBOSE) POLYMERASES; TUBULIN;

EID: 84867843618     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-011-9755-9     Document Type: Article

References (20)

1. Newman DJ, Cragg GM (2007) Natural products as sources of new drugs over the last 25 years. J Nat Prod 70(3):461-477
2. Gusman J, Malonne H, Atassi G (2001) A reappraisal of the potential chemopreventive and chemotherapeutic properties of resveratrol. Carcinogenesis 22(8):1111-1117
3. Baur JA, Sinclair DA (2006) Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov 5(6):493-506
4. Gong YQ, Fan Y, Wu DZ, Yang H, Hu ZB, Wang ZT (2004) In vivo and in vitro evaluation of erianin, a novel anti-angiogenic agent. Eur J Cancer 40(10):1554-1565. doi: 10.1016/j.ejca.2004.01.041S095980490400231X[pii]
5. Gong Y, Fan Y, Liu L, Wu D, Chang Z, Wang Z (2004) Erianin induces a JNK/SAPK-dependent metabolic inhibition in human umbilical vein endothelial cells. In Vivo 18(2):223-228
6. Tozer GM, Prise VE, Wilson J, Locke RJ, Vojnovic B, Stratford MR, Dennis MF, Chaplin DJ (1999) Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues. Cancer Res 59(7):1626-1634
7. Ng TB, Liu F, Wang ZT (2000) Antioxidative activity of natural products from plants. Life Sci 66(8):709-723
8. Polytarchou C, Papadimitriou E (2005) Antioxidants inhibit human endothelial cell functions through down-regulation of endothelial nitric oxide synthase activity. Eur J Pharmacol 510(1-2):31-38
9. Cho M, Hunt TK, Hussain MZ (2001) Hydrogen peroxide stimulates macrophage vascular endothelial growth factor release. Am J Physiol Heart Circ Physiol 280(5):H2357-2363
10. Kuroki M, Voest EE, Amano S, Beerepoot LV, Takashima S, Tolentino M, Kim RY, Rohan RM, Colby KA, Yeo KT, Adamis AP (1996) Reactive oxygen intermediates increase vascular endothelial growth factor expression in vitro and in vivo. J Clin Invest 98(7):1667-1675
11. Hahn SM, DeLuca AM, Coffin D, Krishna CM, Mitchell JB (1998) In vivo radioprotection and effects on blood pressure of the stable free radical nitroxides. Int J Radiat Oncol Biol Phys 42(4):839-842
12. Wang S, Meades C, Wood G, Osnowski A, Anderson S, Yuill R, Thomas M, Mezna M, Jackson W, Midgley C, Griffiths G, Fleming I, Green S, McNae I, Wu SY, McInnes C, Zheleva D, Walkinshaw MD, Fischer PM (2004) 2-Anilino-4-(thiazol-5- yl)pyrimidine CDK inhibitors: synthesis, SAR analysis, X-ray crystallography, and biological activity. J Med Chem 47(7):1662-1675. doi: 10.1021/jm0309957
13. Liu X, Lam F, Shi S, Fischer PM, Wang S. In vitro antitumor mechanism of a novel cyclin-dependent kinase inhibitor CDKI-83. Invest New Drugs. doi: 10.1007/s10637-011-9641-5
14. Liu X, Shi S, Lam F, Pepper C, Fischer PM, Wang S (2011) CDKI-71, a novel CDK9 inhibitor, is preferentially cytotoxic to cancer cells when compared with flavopiridol. Int J Cancer. doi: 10.1002/ijc.26127
15. Lee JC, Timasheff SN (1977) In vitro reconstitution of calf brain microtubules: effects of solution variables. Biochemistry 16(8):1754-1764
16. Chen R, Keating MJ, Gandhi V, Plunkett W (2005) Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death. Blood 106(7):2513-2519
17. Auerbach R, Kubai L, Knighton D, Folkman J (1974) A simple procedure for the long-term cultivation of chicken embryos. Dev Biol 41(2):391-394
18. Li YM, Wang HY, Liu GQ (2001) Erianin induces apoptosis in human leukemia HL-60 cells. Acta Pharmacol Sin 22(11):1018-1022
19. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100(1):57-70
20. Hahn SM, Mitchell JB, Shacter E (1997) Tempol inhibits neutrophil and hydrogen peroxide-mediated DNA damage. Free Radic Biol Med 23(6):879-884